CGTX

Cognition Therapeutics, Inc. Common Stock

$1.25 +5.93%

Recent alerts on CGTX

All signals →

SEC filing CGTX Completes FDA Meeting, Plans Registrational Program for Zervimesine in Dementia with Lewy Bodies with Psychosis

News Cognition Therapeutics GAAP EPS of -$0.05 beats by $0.02

Insider trade Purchase by Lisa Ricciardi (CEO & President)

Insider trade Purchase by Anthony Caggiano (Chief Medical Officer)

Insider trade Purchase by John Brendan Doyle (Chief Financial Officer)

Insider trade Purchase by John Brendan Doyle (Chief Financial Officer)

Insider trade Purchase by Lisa Ricciardi (CEO & President)

Insider trade Purchase by Anthony Caggiano (Chief Medical Officer)

SEC filing CGTX Advances Zervimesine for DLB Psychosis, Cites 86% Slowed Decline in Phase 2 Data

News Veeco Stockholders Approve Merger with Axcelis

Get push alerts for CGTX

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS